RETRACTED: MicroRNA-199b targets the regulation of ZEB1 expression to inhibit cell proliferation, migration and invasion in non-small cell lung cancer (Retracted article. See vol. 26, 2022)

被引:19
作者
Wang, Jin [1 ]
Zhou, Fachen [1 ]
Yin, Liu [1 ]
Zhao, Lei [1 ]
Zhang, Yixiang [1 ]
Wang, Jinguang [1 ]
机构
[1] Dalian Med Univ, Dept Thorac Surg, Affiliated Hosp 1, 222 Zhongshan Rd, Dalian 116011, Liaoning, Peoples R China
关键词
microRNA-199b; non-small cell lung cancer; zinc finger E-box-binding homeobox 1; tumorigenesis; targeted therapy; METASTASIS; SUPPRESSES; PROGNOSIS;
D O I
10.3892/mmr.2017.7195
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lung cancer is one of the leading causes of cancer-associated mortality worldwide. Previous evidence suggested that microRNAs (miRs) exhibit important regulatory roles in tumorigenesis and tumor development, including in non-small cell lung cancer (NSCLC). The present study investigated the expression of miR-199b in NSCLC tissues and cell lines, in addition to the biological roles of miR-199b in the carcinogenesis and progression of NSCLC. The results of the present study demonstrated that miR-199b expression was decreased in NSCLC tissues and cell lines compared with matched adjacent healthy tissues and a healthy human bronchial epithelial cell line, respectively. An MTT assay demonstrated that the viability of NSCLC cells was decreased by miR-199b. The migratory and invasive abilities of NSCLC cells were suppressed by miR-199b overexpression. In addition, zinc finger E-box-binding homeobox 1 (ZEB1) was identified to be a novel direct downstream and functional target for miR-199b in NSCLC, using bioinformatics analysis, luciferase reporter assay, the reverse transcription-quantitative polymerase chain reaction and western blotting. ZEB1 underexpression mimicked the roles of miR-199b overexpression in NSCLC cells. In conclusion, the present study demonstrated that miR-199b was downregulated in NSCLC and acted as a tumor suppressor by targeting ZEB1.
引用
收藏
页码:5007 / 5014
页数:8
相关论文
共 26 条
[1]   The functions of animal microRNAs [J].
Ambros, V .
NATURE, 2004, 431 (7006) :350-355
[2]   MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29
[3]   MicroRNA signatures in human cancers [J].
Calin, George A. ;
Croce, Carlo M. .
NATURE REVIEWS CANCER, 2006, 6 (11) :857-866
[4]   Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma [J].
Chao, Angel ;
Tsai, Chia-Lung ;
Wei, Pei-Chi ;
Hsueh, Swei ;
Chao, An-Shine ;
Wang, Chin-Jung ;
Tsai, Chi-Neu ;
Lee, Yun-Shien ;
Wang, Tzu-Hao ;
Lai, Chyong-Huey .
CANCER LETTERS, 2010, 291 (01) :99-107
[5]   miRNAs, cancer, and stem cell division [J].
Croce, CM ;
Calin, GA .
CELL, 2005, 122 (01) :6-7
[6]   MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer [J].
Cui, Ri ;
Meng, Wei ;
Sun, Hui-Lung ;
Kim, Taewan ;
Ye, Zhenqing ;
Fassan, Matteo ;
Jeon, Young-Jun ;
Li, Bin ;
Vicentini, Caterina ;
Peng, Yong ;
Lee, Tae Jin ;
Luo, Zhenghua ;
Liu, Lan ;
Xu, Dongyuan ;
Tili, Esmerina ;
Jin, Victor ;
Middleton, Justin ;
Chakravarti, Arnab ;
Lautenschlaeger, Tim ;
Croce, Carlo M. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (31) :E4288-E4297
[7]   MiR-199b-5p targets HER2 in breast cancer cells [J].
Fang, Chen ;
Zhao, Yu ;
Guo, Baoyu .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2013, 114 (07) :1457-1463
[8]   miR-199b, a novel tumor suppressor miRNA in acute myeloid leukemia with prognostic implications [J].
Favreau A.J. ;
McGlauflin R.E. ;
Duarte C.W. ;
Sathyanarayana P. .
Experimental Hematology & Oncology, 5 (1)
[9]   RETRACTED: miR-215 functions as a tumor suppressor and directly targets ZEB2 in human non-small cell lung cancer (Retracted article. See vol. 22, 2021) [J].
Hou, Yan ;
Zhen, Junwen ;
Xu, Xiaodong ;
Zhen, Kun ;
Zhu, Bin ;
Pan, Rui ;
Zhao, Chidong .
ONCOLOGY LETTERS, 2015, 10 (04) :1985-1992
[10]   Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients [J].
Joshi, Dolly ;
Chandrakala, S. ;
Korgaonkar, Seema ;
Ghosh, Kanjaksha ;
Vundinti, Babu Rao .
GENE, 2014, 542 (02) :109-112